Ventus Therapeutics, which is developing therapies aimed at diseases of the innate immune system, closed a $140 million Series C financing round that will be used to drive three lead programs into the clinic during 2022.
Pfizer is expanding the company’s presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and the lead antifungal compound Fosmanogepix (APX001).
Caribou Biosciences secured $115 million in an oversubscribed Series C financing round that will be used to advance the company’s pipeline of wholly owned allogeneic immune cell therapies for oncology and its next-generation CRISPR technology platform.
Business updates for various pharma and life science companies around the globe.
Less than one month after filing for bankruptcy, uBiome is shutting the Bay Area microbiome company’s doors and selling off assets.